Foscavir Mechanism of Action-How It Inhibits Viral DNA Polymerase

1. Foscavir Mechanism of Action: How It Inhibits Viral DNA Polymerase Introduction: Role of antivirals in CMV and HSV infections Herpes simplex virus (HSV) and cytomegalovirus (CMV) infections are commonly seen in immunocompromised patients, particularly in patients with HIV. However, fulminant CMV infection andconcurrent infection with HSV and CMV in non-HIV patients are quite rare.1 CMV can lead to severe retinitis and end-organ disease, especially in people with AIDS,2 HSV can produce stubborn mucocutaneous lesions and infections.3 CMV and HSV infection can occur simultaneously at distinct sites in the body, and CMV infection may predispose to HSV reactivation due to its long-term effect on cell-mediated immunity. Early recognition of opportunistic infections in immunocompromised patients can affect length of hospital stay, morbidity, and, ultimately, mortality.1 Antiviral drugs inhibit CMV replication by interfering with viral DNA synthesis.4 Oral antiviral medications have been shown to decrease the severity of symptoms, reduce the duration of pain, accelerate lesion healing, and minimize viral shedding in patients experiencing their first episode of primary genital HSV infection.5 What is Foscavir (Foscarnet Sodium)? Foscavir (foscarnet sodium) is an intravenous antiviral medication used for viral infections that do not respond well to standard first-line therapies. Because of its nephrotoxic potential and the risk of electrolyte imbalances, it requires careful monitoring and specialized management during treatment to balance efficacy with patient safety. 6 Mechanism of Action: DNA Polymerase Inhibition Foscavir (foscarnet sodium) is a pyrophosphate analogue that inhibits viral replication by binding directly to the viral DNA polymerase enzyme, preventing the removal of pyrophosphate and thereby halting DNA chain elongation. This mechanism effectively blocks viral DNA synthesis without requiring activation by viral kinases. It selectively targets viral polymerases; and athigh concentrations, it can also inhibit human DNA polymerase, althoughsuch doses are rarely needed. Resistance to foscarnet may occur due to mutations in the UL54 gene, which alter the drug’s binding site and reduce its effectiveness.6 Approved Indications

2. •CMV Retinitis in AIDS Patients: FDA-approved for the treatment of CMV retinitis in individuals with AIDS who cannot tolerate ganciclovir. •Drug-Resistant CMV: Serves as salvage therapy for patients with CMV infections unresponsive to ganciclovir. •Acyclovir-Resistant HSV: Approved for mucocutaneous HSV infections in immunocompromised patients who fail to respond to acyclovir. Important Note: Foscavir is not an antiretroviral and has no activity against HIV.6 Safety Profile and Key Side Effects Foscavir is associated with a range of side effects: •Nausea and other gastrointestinal symptoms •Nephrotoxicity (acute kidney injury, tubular damage, crystal nephropathy) may trigger seizures. •Electrolyte imbalances (hypocalcemia, hypomagnesemia, hypokalemia) •Genital ulcers (more common in males) •Arginine vasopressin resistance (AVP-R) / nephrogenic diabetes insipidus •QT prolongation and torsades de pointes •Anemia Warnings to be kept in mind when using Foscavir:6 •Foscarnet can cause serious kidney damage. Regular renal function monitoring and adequate hydration are essential. •It is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis, angioedema). Here are the precautions you can take when on Foscavir.6 Cardiac caution: Foscarnet should be administered with caution in patients with pre-existing cardiac abnormalities, including abnormal electrocardiograms, due to potential proarrhythmic effects. Renal impairment: The drug is contraindicated in patients with chronic kidney disease or significantly reduced creatinine clearance, given its nephrotoxic potential.

3. Electrolyte management: Pre-existing electrolyte disturbances, particularly hypocalcemia, hypomagnesemia, and hypokalemia, must be corrected before initiating foscarnet therapy to reduce the risk of adverse events, including seizures and arrhythmias. Seizure risk: Use with caution in patients with a history of seizure disorders, as foscarnet- induced electrolyte imbalances can precipitate convulsions. Hemodialysis: Foscarnet is not recommended for patients undergoing hemodialysis due to altered pharmacokinetics and an increased risk of toxicity. Hepatic effects: Mild to moderate elevations in liver enzymes (ALT) may occur during therapy, typically resolving upon discontinuation of the medication. Rare cases of cholestatic liver injury have also been documented. Pregnancy: Foscarnet should only be used during pregnancy if the potential benefits outweigh the risks, as animal studies indicate potential skeletal malformations even at low doses. Breastfeeding: The excretion of Foscavir is excreted in human breast milk is unknown. Animal studies show high levels in milk; therefore, breastfeeding should be avoided during therapy, particularly in HIV-positive mothers. Pediatric considerations: Foscarnet may deposit in developing bones and teeth, potentially causing enamel hypoplasia. Safety in pediatric populations is not fully established; close monitoring of renal and skeletal health is recommended. Geriatric use: Dose adjustments may be required in elderly patients due to age-related decline in renal function, which increases the risk of toxicity. Conclusion Foscavir is a critical antiviral option for managing difficult-to-treat viral infections, particularly CMV retinitis in AIDS patients and acyclovir-resistant HSV in immunocompromised individuals. It directly inhibits viral DNA polymerase, making it effective where standard antivirals may fail. Due to risks such as nephrotoxicity, electrolyte imbalances, and seizures, careful monitoring of renal, electrolyte, liver, and cardiac function is essential. With careful patient selection and monitoring, Foscavir can be a pragmatic choice for managing viral infections in high-risk patients. Note:

4. This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions regarding a medical condition or treatment. Disclaimer: Rx4U procures prescribed medicines directly from manufacturers or authorized distributors. It does not claim ownership of any trademarks and complies with the provisions of the Trademark Act, 1999, particularly Sections 30 and 30(1) concerning ‘Fair Use’. It solely facilitates access to new launches through named patient import. References 1.Gangemi AC, Choi SH, Yin Z, Feurdean M. Cytomegalovirus and Herpes Simplex Virus Co-Infection in an HIV-Negative Patient: A Case Report. Cureus [Internet]. 13(2):e13214. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946604/ 2.Dujić M, Jevtović Dj, Salemović D, Ranin J, Brmbolić B, Djurković-Djaković O. The prognosis of CMV retinitis among patients with AIDS in Serbia. Biomedicine & Pharmacotherapy [Internet]. 2008 Jan 14;62(7):443–7. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0753332207002958 3.Herpes Simplex Virus | NIH [Internet]. clinicalinfo.hiv.gov. HIVinfo.NIH.gov; 2020. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult- and-adolescent-opportunistic-infections/herpes-simplex 4.Shim G. Treatment of Congenital Cytomegalovirus Infection. Clinical and Experimental Pediatrics. 2022 Dec 28;66(9):384–94. 5.Nagarakanti SR, Zikri AM. Is there a role for chronic suppressive therapy in herpes simplex virus infection? Cleveland Clinic Journal of Medicine [Internet]. 2024 Mar 1;91(3):151–3. Available from: https://www.ccjm.org/content/91/3/151#:~:text=There%20is%20no%20cure%20for 6.Garikapati S, Nguyen M. Foscarnet [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556108/